BridgeBio Pharma (BBIO) Income from Continuing Operations (2018 - 2026)
BridgeBio Pharma recorded quarterly Income from Continuing Operations of 112652000.0 in Q1 2026, up 42.12% quarter-over-quarter from 194635000.0 in Q4 2025, and up 3.81% year-over-year from 108522674.61 in Q1 2025.
BridgeBio Pharma's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 112652000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 3.81% year-over-year to 112652000.0; the TTM figure through Mar 2026 stood at 676027000.0 (down 8.29% YoY), while the FY2025 annual figure was 732938000.0, down 34.89% from the prior year.
- Income from Continuing Operations came in at 112652000.0 for Q1 2026 at BridgeBio Pharma, up from 194635000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 19053000.0 in Q1 2024 to a low of 267389000.0 in Q4 2024.
- A 5-year average of 151476117.65 and a median of 162179000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 86.59% in 2024 and slumped 514.64% in 2025, its largest moves.
- BridgeBio Pharma's Income from Continuing Operations stood at 145130000.0 in 2022, then sank by 32.37% to 192106000.0 in 2023, then plunged by 39.19% to 267389000.0 in 2024, then gained by 27.21% to 194635000.0 in 2025, then surged by 42.12% to 112652000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 112652000.0, 194635000.0, and 184982000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -112.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112.65 Mn |
| Dec 31, 2025 | -194.64 Mn |
| Sep 30, 2025 | -184.98 Mn |
| Jun 30, 2025 | -183.76 Mn |
| Mar 31, 2025 | -117.11 Mn |
| Dec 31, 2024 | -267.39 Mn |
| Sep 30, 2024 | -164.25 Mn |
| Jun 30, 2024 | -75.54 Mn |
| Mar 31, 2024 | -19.05 Mn |
| Dec 31, 2023 | -192.11 Mn |
| Sep 30, 2023 | -174.21 Mn |
| Jun 30, 2023 | -162.18 Mn |
| Mar 31, 2023 | -142.13 Mn |
| Dec 31, 2022 | -145.13 Mn |
| Sep 30, 2022 | -146.52 Mn |
| Jun 30, 2022 | -99.69 Mn |
| Mar 31, 2022 | -193.76 Mn |
| Dec 31, 2021 | -180.57 Mn |
| Sep 30, 2021 | -160.33 Mn |
| Jun 30, 2021 | -104.53 Mn |
| Mar 31, 2021 | -176.85 Mn |
| Dec 31, 2020 | -138.00 Mn |
| Sep 30, 2020 | -130.18 Mn |
| Jun 30, 2020 | -134.39 Mn |
| Mar 31, 2020 | -104.56 Mn |
| Dec 31, 2019 | -79.27 Mn |
| Sep 30, 2019 | -53.91 Mn |
| Jun 30, 2019 | -69.60 Mn |
| Mar 31, 2019 | -63.32 Mn |
| Dec 31, 2018 | -65.29 Mn |
| Sep 30, 2018 | -42.08 Mn |
| Jun 30, 2018 | -34.99 Mn |